ATE531713T1 - Polymorphin von 5-ä4-ää3-methyl-4-oxo-3,4- dihydrochinazolin-2-ylümethoxyübenzylü thiazolidin-2,4-dion kalium salz - Google Patents
Polymorphin von 5-ä4-ää3-methyl-4-oxo-3,4- dihydrochinazolin-2-ylümethoxyübenzylü thiazolidin-2,4-dion kalium salzInfo
- Publication number
- ATE531713T1 ATE531713T1 AT05077388T AT05077388T ATE531713T1 AT E531713 T1 ATE531713 T1 AT E531713T1 AT 05077388 T AT05077388 T AT 05077388T AT 05077388 T AT05077388 T AT 05077388T AT E531713 T1 ATE531713 T1 AT E531713T1
- Authority
- AT
- Austria
- Prior art keywords
- thiazolidine
- oxo
- methyl
- potassium salt
- ylümethoxyübenzylü
- Prior art date
Links
- NIGXDLPSDCSMNR-UHFFFAOYSA-N potassium;1,3-thiazolidine-2,4-dione Chemical compound [K].O=C1CSC(=O)N1 NIGXDLPSDCSMNR-UHFFFAOYSA-N 0.000 title 1
- IETKPTYAGKZLKY-UHFFFAOYSA-N 5-[[4-[(3-methyl-4-oxoquinazolin-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound N=1C2=CC=CC=C2C(=O)N(C)C=1COC(C=C1)=CC=C1CC1SC(=O)NC1=O IETKPTYAGKZLKY-UHFFFAOYSA-N 0.000 abstract 1
- WIMXIELKVIGBNM-UHFFFAOYSA-N 5-[[4-[(3-methyl-4-oxoquinazolin-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione;potassium Chemical compound [K].N=1C2=CC=CC=C2C(=O)N(C)C=1COC(C=C1)=CC=C1CC1SC(=O)NC1=O WIMXIELKVIGBNM-UHFFFAOYSA-N 0.000 abstract 1
- 238000001816 cooling Methods 0.000 abstract 1
- 238000001938 differential scanning calorimetry curve Methods 0.000 abstract 1
- 238000001035 drying Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000003960 organic solvent Substances 0.000 abstract 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 abstract 1
- 239000002244 precipitate Substances 0.000 abstract 1
- 238000003756 stirring Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN180MA2002 | 2002-03-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE531713T1 true ATE531713T1 (de) | 2011-11-15 |
Family
ID=33397665
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05077388T ATE531713T1 (de) | 2002-03-15 | 2003-03-14 | Polymorphin von 5-ä4-ää3-methyl-4-oxo-3,4- dihydrochinazolin-2-ylümethoxyübenzylü thiazolidin-2,4-dion kalium salz |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8377950B2 (enExample) |
| EP (2) | EP1487830A1 (enExample) |
| JP (2) | JP4634716B2 (enExample) |
| AT (1) | ATE531713T1 (enExample) |
| AU (1) | AU2003209562A1 (enExample) |
| ES (1) | ES2373446T3 (enExample) |
| WO (1) | WO2003078425A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7906678B2 (en) | 2006-12-04 | 2011-03-15 | Bayer Schering Pharma Aktiengesellschaft | Crystalline potassium salt of lipoxin A4 analogs |
| EP2155756B1 (en) * | 2007-05-30 | 2015-08-05 | Wockhardt Limited | Processes for the preparation of clopidogrel |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE246190T1 (de) | 1996-12-31 | 2003-08-15 | Reddys Lab Ltd Dr | Heterozyklische verbindungen, verfahren zu ihrer herstellung, pharmazeutische zusammensetzungen die diese enthalten und ihre anwendung in der behandlung von diabetis und verwandten krankheiten |
| IN187716B (enExample) * | 1998-09-14 | 2002-06-15 | Reddy Research Foundation |
-
2003
- 2003-03-14 ES ES05077388T patent/ES2373446T3/es not_active Expired - Lifetime
- 2003-03-14 US US10/507,399 patent/US8377950B2/en not_active Expired - Fee Related
- 2003-03-14 WO PCT/IB2003/000935 patent/WO2003078425A1/en not_active Ceased
- 2003-03-14 JP JP2003576430A patent/JP4634716B2/ja not_active Expired - Fee Related
- 2003-03-14 EP EP03744465A patent/EP1487830A1/en not_active Ceased
- 2003-03-14 AT AT05077388T patent/ATE531713T1/de active
- 2003-03-14 EP EP05077388A patent/EP1623984B1/en not_active Expired - Lifetime
- 2003-03-14 AU AU2003209562A patent/AU2003209562A1/en not_active Abandoned
-
2010
- 2010-07-29 JP JP2010171223A patent/JP2010248246A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US20050234079A1 (en) | 2005-10-20 |
| EP1487830A1 (en) | 2004-12-22 |
| EP1623984B1 (en) | 2011-11-02 |
| AU2003209562A1 (en) | 2003-09-29 |
| JP4634716B2 (ja) | 2011-02-16 |
| WO2003078425A1 (en) | 2003-09-25 |
| JP2005523300A (ja) | 2005-08-04 |
| JP2010248246A (ja) | 2010-11-04 |
| ES2373446T3 (es) | 2012-02-03 |
| EP1623984A1 (en) | 2006-02-08 |
| US8377950B2 (en) | 2013-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0013237A (pt) | Fenil oxazolidinonas substituìdas heterobiciclicas antibacterianas | |
| EP1968131A4 (en) | MATERIAL FOR AN ORGANIC ELECTROLUMINESCENCE DEVICE AND ORGANIC ELECTROLUMINESCENCE DEVICE | |
| DE602005023343D1 (de) | Pyrimidinderivate als gpcr-agonisten | |
| ATE299530T1 (de) | Reversible inaktivierung von enzymen | |
| ATE420078T1 (de) | Pyrimidinonen als virale polymerase inhibitoren | |
| ATE401312T1 (de) | Pyrimidin-5-carboxamid-derivate | |
| PE20090774A1 (es) | Compuestos heterociclicos como moduladores de la enzima dgat1 | |
| PE20051159A1 (es) | Derivados de heteroarilaminopirazol como estimulantes de la produccion de insulina | |
| ATE531713T1 (de) | Polymorphin von 5-ä4-ää3-methyl-4-oxo-3,4- dihydrochinazolin-2-ylümethoxyübenzylü thiazolidin-2,4-dion kalium salz | |
| BR0000962A (pt) | Processo para a preparação de 2-cloro-5-clorometil tiazol | |
| EP1136470A4 (en) | METHOD FOR PRODUCING A PIPERAZINE DERIVATIVE | |
| ID24210A (id) | Proses produksi selektif z-isomer dari 3-(2-tersubstitusi vinil)-cepalosporin | |
| US3265706A (en) | Processes for preparing certain 2-substituted benzimidazole compounds | |
| Khidre et al. | Design and synthesis of some new thiophene and 1, 3, 4-thiadiazole based heterocycles | |
| CO5221077A1 (es) | Ariloxipropanolaminas para mejorar la produccion del ganado | |
| CY1108241T1 (el) | Πυριδυλσουλφοναμιδο πυριμιδινες για την θεραπεια της διαβητικης νεφροπαθειας | |
| AR090619A2 (es) | Uso de un compuesto de tiazol para la produccion de un medicamento | |
| Megahed et al. | Synthesis and Antimicrobial Activity of Methyl 2‐(2‐(2‐Arylquinazolin‐4‐yl) sulfanyl) acetylamino Alkanoates | |
| Reddy et al. | Synthesis and antimicrobial activity of amino linked heterocycles | |
| DE10343757A1 (de) | Verfahren zur Schwermetall-freien Herstellung von N,N'-persubstituierten 5,5'-Diamino-2,2'bithiophenen und 2,2'-Diamino-5,5'-bithiazolen sowie deren Verwendung | |
| ATE454376T1 (de) | Herstellung von 1,7( -dimethyl-2( -propyl-2,5( - bi-1h-benzimidazol | |
| YU46081B (sh) | Postupak za dobijanje derivata gvanidina | |
| TR200200847T2 (tr) | Sulfohalojenür'lerden sübstitüe edilmiş fenil sulfonil ürelerin üretilmesine mahsus yöntem | |
| US6465492B1 (en) | Heterocyclic compounds | |
| FR2705098B1 (fr) | Procédé de préparation de 2-{4-[4-(chloro-1-pyrazolyl)butyl]1-pipérazinyl}pyrimidine (Lesopitron) . |